Peer-influenced content. Sources you trust. No registration required. This is HCN.
MedCentral
With FDA Priority Review underway, baxdrostat may become the first aldosterone synthase inhibitor available for patients with uncontrolled or treatment‑resistant hypertension.
Cardiology April 21st 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS